Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 8Other solid neoplasm 4Genitourinary 4CNS 4Tumor-Agnostic 3Thoracic 3Sarcoma 3Gastrointestinal 3Breast 3Head & Neck 2

Conditions

Glioblastoma 4Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 623Radiotherapy 410Bevacizumab 256Magnetic Resonance Spectroscopy 226Cyclophosphamide 179Radiosurgery 162Carboplatin 160Etoposide 132Radiation 128Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 83Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
pamiparib × CNS × Clear all
NCT04614909 2026-05-14

Study of Pamiparib in Newly Diagnosed and rGBM

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Completed
50 enrolled
CNS

Glioblastoma

NCT03749187 2026-03-13

PNOC017

University of California, San Francisco

Phase 1 Active not recruiting
78 enrolled
CNS

Glioblastoma, Glioma

NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

BeiGene

Phase 1/2 Completed
116 enrolled 31 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT03914742 2025-01-14

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
67 enrolled 18 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡